About Us  |  Contact Us  |  Español
VNA of Care New England
VNA of Care New England

FDA: New Test Helps Diagnose Intellectual Disability in Children

Scan tracks entire genome from a blood sample
FRIDAY, Jan. 17, 2014 (HealthDay News) -- A new test to diagnose developmental delays and intellectual disability in children based on genetic abnormalities has been approved by the U.S. Food and Drug Administration.
The Affymetrix CytoScan DX Assay scans the entire genome from a blood sample and detects chromosomal variations that can lead to developmental and learning problems in children, the agency said Friday in a news release.
Intellectual disability affects as many as 3 percent of children in the United States, the agency said.
Analysis of 960 blood specimens found the new test was better at detecting chromosomal abnormalities that could lead to intellectual disability than other standard tests, the FDA said.
The new test is produced by Affymetrix Inc., based in Santa Clara, Calif.
More Information (http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm382179.htm )
Health Headlines
FDA Expands Use of Imbruvica for Form of LeukemiaView in a lightbox
'Fist Bump' May Beat Handshake for CleanlinessView in a lightbox
CDC Downplays Ebola's Threat to the United StatesView in a lightbox
Heat Stroke a Greater Threat to Endurance Runners Than Heart Problems: StudyView in a lightbox
Running Could Add 3 Years to Your LifespanView in a lightbox
VNA of Care New England
© 2011 Site Index | Disclaimer | Legal Notices